ITGAV: A Potential Drug Target in Diseases (G3685)

Target Name: ITGAV

NCBI ID: G3685

ITGAV

ITGAV: A Potential Drug Target in Diseases

ITGAV (ITGAV variant 3) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the integrin alpha-2 (ITGA2) family, which is characterized by the presence of a variable region of the protein that contains a nucleotide-binding oligomerization domain (NBD) and a cytoplasmic domain. The ITGA2 family plays a role in cell adhesion, migration, and invasion, and is involved in many physiological processes, including tissue repair, inflammation, and fetal development.

Recent studies have identified ITGAV as a potential drug target in the context of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because ITGAV is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent the passage of harmful substances into the body. dysfunction, such as cancer, neurodegenerative diseases, and autoimmune disorders.

ITGAV variant 3 has been shown to be overexpressed in various diseases, including neurodegenerative diseases, cancer, and autoimmune disorders. This suggests that ITGAV may be a useful biomarker or drug target in these diseases.

The ITGAV protein is composed of a variable region that contains a nucleotide-binding oligomerization domain (NBD) and a cytoplasmic domain. The NBD is a protein that is involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent the passage of harmful substances into the body. The cytoplasmic domain of ITGAV contains a region that is involved in the interaction with the cytoplasm and the cell surface.

Studies have shown that ITGAV is involved in the formation of tight junctions in various tissues of the body. For example, it has been shown to be involved in the formation of tight junctions in the brain, heart, and kidneys. This suggests that ITGAV may be involved in the development and progression of these diseases.

In addition to its role in tight junction formation, ITGAV is also involved in the regulation of cell adhesion and migration. For example, studies have shown that ITGAV is involved in the regulation of cell adhesion in various tissues, including the brain and the placenta. It is also involved in the regulation of cell migration, as has been shown to be involved in the migration of neurons in the brain.

The ITGAV protein has also been shown to be involved in the regulation of cellular signaling pathways. For example, studies have shown that ITGAV is involved in the regulation of the PI3K/Akt signaling pathway, which is a pathway that is involved in the regulation of cellular signaling pathways. This suggests that ITGAV may be involved in the development and progression of diseases that are characterized by the disruption of cellular signaling pathways.

In conclusion, ITGAV is a protein that is involved in the formation of tight junctions, the regulation of cell adhesion and migration, and the regulation of cellular signaling pathways. This suggests that ITGAV may be a useful biomarker or drug target in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to determine the full role of ITGAV in these diseases.

Protein Name: Integrin Subunit Alpha V

Functions: The alpha-V (ITGAV) integrins are receptors for vitronectin, cytotactin, fibronectin, fibrinogen, laminin, matrix metalloproteinase-2, osteopontin, osteomodulin, prothrombin, thrombospondin and vWF. They recognize the sequence R-G-D in a wide array of ligands. ITGAV:ITGB3 binds to fractalkine (CX3CL1) and may act as its coreceptor in CX3CR1-dependent fractalkine signaling (PubMed:23125415). ITGAV:ITGB3 binds to NRG1 (via EGF domain) and this binding is essential for NRG1-ERBB signaling (PubMed:20682778). ITGAV:ITGB3 binds to FGF1 and this binding is essential for FGF1 signaling (PubMed:18441324). ITGAV:ITGB3 binds to FGF2 and this binding is essential for FGF2 signaling (PubMed:28302677). ITGAV:ITGB3 binds to IGF1 and this binding is essential for IGF1 signaling (PubMed:19578119). ITGAV:ITGB3 binds to IGF2 and this binding is essential for IGF2 signaling (PubMed:28873464). ITGAV:ITGB3 binds to IL1B and this binding is essential for IL1B signaling (PubMed:29030430). ITGAV:ITGB3 binds to PLA2G2A via a site (site 2) which is distinct from the classical ligand-binding site (site 1) and this induces integrin conformational changes and enhanced ligand binding to site 1 (PubMed:18635536, PubMed:25398877). ITGAV:ITGB3 and ITGAV:ITGB6 act as receptors for fibrillin-1 (FBN1) and mediate R-G-D-dependent cell adhesion to FBN1 (PubMed:12807887, PubMed:17158881). Integrin alpha-V/beta-6 or alpha-V/beta-8 (ITGAV:ITGB6 or ITGAV:ITGB8) mediates R-G-D-dependent release of transforming growth factor beta-1 (TGF-beta-1) from regulatory Latency-associated peptide (LAP), thereby playing a key role in TGF-beta-1 activation (PubMed:15184403, PubMed:22278742, PubMed:28117447). ITGAV:ITGB3 acts as a receptor for CD40LG (PubMed:31331973)

The "ITGAV Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITGAV comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets